Given the rise in metabolic diseases a sustained increase in the prevalence of chronic liver diseases such as metabolic dysfunction-associated steatotic liver disease (MASLD) is expected. The progression of chronic liver diseases leads to increased liver-specific and life-threatening complications, such as impaired liver regeneration, fibrosis, cirrhosis and hepatocellular carcinoma (HCC), which represent an enormous burden for the future. In the dynamic landscape of metabolic and cancer research, understanding the complex mechanisms of liver regeneration, fibrosis and hepatocarcinogenesis is crucial. Numerous alterations trigger pathological cellular signaling initiating steatosis, inflammation, fibrogenesis and malignant transformations. While targeted therapies and immunotherapies have advanced, enhancing their efficacy remains a critical concern. Our research focuses on liver regeneration, MASLD, fibrosis and HCC, aiming to identify new vulnerabilities within these diseases and integrate them into treatment strategies. Using state of the art techniques such as genetic screenings, different in-vitro and in vivo models, combining experimental and clinical data, we pioneer innovative approaches for managing liver diseases. Additionally, our laboratory investigates the immune signatures of chronic inflammatory conditions, shedding light on the interaction between lifestyle factors and pathogens in chronic liver diseases.
By elucidating the molecular and cellular pathways, we aim to address the urgent global health challenge presented by the rising prevalence of chronic liver dieseases.
